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Abstract. Melatonin, the main secretory product of the 
pineal gland, is an oncostatic agent that reduces the growth 
and development of various types of tumors, particularly 
mammary tumors whose growth is dependent on estrogens. 
Previous in vivo and in vitro studies point to the hypothesis 
that melatonin interplays with estrogen signaling pathways 
at three different levels: i) an indirect mechanism, by inter-
fering with the hypothalamic-pituitary-reproductive axis in 
such way that the level of plasma estrogens synthesized by 
the gonadal glands are downregulated; ii) a direct mecha-
nism of the pineal gland at the cell cancer level, disrupting 
the activation of estradiol receptors, therefore behaving as a 
selective estrogen receptor modulator; and iii)  by regulating 
the enzymes involved in the biosynthesis of estrogens in 
other tissues, thus behaving as a selective estrogen enzyme 
modulator. The intratumoral metabolism and synthesis of 
estrogens, as a result of the interactions of various enzymes, 
is more important than blood uptake to maintain mammary 
gland estrogen levels in menopausal females. Additionally, 
estrogens are considered to play an important role in the 
pathogenesis and development of hormone-dependent 
breast carcinoma. Paracrine interactions among malignant 
epithelial cells and proximal adipose and endothelial cells, 
through cytokines and growth factors produced by breast 
tumor cells, modulate estrogen production at the mammary 
tumor level and, as a consequence, the genesis and develop-
ment of mammary tumors. The aim of the present review 
is to summarize the recent findings describing the mecha-
nisms by which melatonin is able to modulate the crosstalk 




2. Local synthesis of estrogens in breast cancer epithelial 
 cells and melatonin
3. Local synthesis of estrogens in peritumoral fibroblasts and 
 melatonin
4. Local synthesis of estrogens in peritumoral endothelial 
 cells and melatonin
5. Conclusions
1. Introduction
The oncostatic effects of melatonin are particularly relevant to 
hormone-dependent tumors (1-5). Of these neoplasias, the most 
deeply studied have been mammary adenocarcinomas. Based 
on the role of the pineal gland in inhibiting gonadal maturation 
and sex hormone secretion in mammals, Cohen et al (1978) 
introduced the hypothesis that a decrease in pineal function 
decreases melatonin levels and induces a relative ‘hyperestro-
genism’, which underlies the development of breast cancer (6). 
Since then, there has been evidence supporting the theory that 
the antitumor actions of melatonin in hormone-dependent 
tumors are mainly based on the antiestrogenic properties of 
melatonin (5,7).
The oncostatic effects of melatonin in hormone-dependent 
breast cancer were firstly explained by indirect neuroendocrine 
mechanisms, such as the downregulation of the neuroen-
docrine reproductive axis by melatonin, and the consequent 
reduction of estrogenic hormones responsible for the normal 
and pathological growth of the mammary gland (8). In addi-
tion, it has also been demonstrated that melatonin may directly 
interfere with the activation of the estrogen receptor and 
counteract the effects of estrogens at the tumor cell level, thus 
behaving as a selective estrogen receptor modulator (7,9-11). 
In more recent years, a third neuroendocrine mechanism 
has been described in which melatonin is able to reduce the 
estrogen-mediated development of breast cancer, involving 
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the regulation of certain enzymes responsible for the local 
synthesis of estrogens, thus behaving as a selective estrogen 
enzyme modulator (12-15).
2. Local synthesis of estrogens in breast cancer epithelial 
cells and melatonin
The intratumoral metabolism and synthesis of estrogens, as a 
result of the interactions of various enzymes, is considered to 
play an important role in the pathogenesis and development 
of hormone-dependent breast carcinoma (16-19). In breast 
cancer, particularly that of postmenopausal women, estrogens 
are synthesized in the mammary tissue by transformation 
either from androgen precursors, mainly of adrenal origin, 
or from biologically inactive estrogens. Breast carcinoma 
epithelial cells contain all the enzymes necessary for the local 
synthesis of estrogens (Fig. 1). One of the major pathways 
involved in the synthesis of estrogens in breast cancer cells 
is the aromatase pathway, which transforms androgens into 
estrogens (20). Aromatase activity and expression is mark-
edly higher in breast cancer tissue than in normal mammary 
tissue (21,22). The second pathway involved in estrogen 
formation is the sulfatase pathway, which converts estrogen 
sulfates into estrone and estradiol (18,19,22). The final step of 
steroidogenesis in peripheral tissues is the conversion of the 
weak estrone to the potent biologically active estradiol by 
the action of the 17β-hydroxysteroid dehydrogenase activity 
type 1 (17β-HSD1) (18,19). In breast cancer tissue, estrogen 
sulfotransferase is also present, which converts estrogens into 
estrogen sulfates. Since the sulfo-conjugated estrogens are the 
biologically inactive forms of the estrogens, another possible 
way to control the tissular concentration of active estradiol is 
to identify new ways to stimulate the enzymes involved in the 
sulfate formation (19,22). 
In normal breast tissue, there is a high concentration of 
circulating inactive steroids, which are the major precursor 
substrates of local estrogen production, mainly estrone. In this 
tissue, the estrogen sulfotransferase activity and expression, 
the enzyme that inactivates estrone and 17β-estradiol, tend to 
be increased. However, in breast carcinoma tissue, aromatase 
(which converts androgens into estrogens), sulfatase (which 
hydrolyzes the estrone sulfates to estrone) and 17β-HSD1 
(which converts the estrone to the potent 17β-estradiol) tend 
to be overexpressed, whereas the expression of estrogen sulfo-
transferase is frequently decreased, which may result in the 
accumulation of 17β-estradiol in breast cancer tissues (Fig. 2). 
At the tumor cell level, melatonin decreases the activity 
and expression of aromatase, sulfatase and 17β-HSD1, and 
increases the activity and expression of estrogen sulfotrans-
ferase (12,13,23,24). Melatonin tends to modify the activity 
and expression of the enzymes involved in the local synthesis 
of estrogens, causing them to be similar to the expression of 
enzymes in the mammary normal tissue, and may thus protect 
mammary tissue from excessive estrogenic effects (Fig. 2).
Regulation of aromatase expression in human tissues 
is relatively complex, involving alternative promoter sites 
that provide tissue‑specific control. In the normal breast, the 
mammary adipose tissue maintains low levels of aromatase 
expression almost exclusively via promoter I.4 (25). However, 
in mammary cancer, both in malignant epithelial cells and 
fibroblasts, the expression of aromatase is increased via acti-
vation of promoters II and I.3, which are regulated by cyclic 
adenosine monophosphate (cAMP) and factors that regulate 
cAMP levels (26). Prostaglandin E2 (PGE2) is an important 
regulator of aromatase gene expression via promoters II 
and I.3 (25-28). The formation of PGE2 occurs through the 
activity of the cyclooxygenases (COXs), rate-limiting enzymes 
that catalyze the conversion of arachidonic acid to prosta-
glandins. Promoter I.3 and II are considered to be the major 
promoters driving aromatase expression in breast cancer and 
surrounding adipose tissue. One of the mechanisms through 
which melatonin modulates aromatase enzyme in breast tumor 
cells is through its downregulatory action on the expression of 
COX enzymes, COX-1 and COX-2, which decrease the levels 
of PGE2. Lower levels of PGE2 result in decreased intracel-
lular levels of cAMP, which in turn diminish the activation 
Figure 1. Enzymatic mechanisms involved in the local production of estro-
gens in human breast carcinoma tissues. DHEA, dehydroepiandrosterone; 
DHEA-S, DHEA sulfate; 17β‑HSD type 1, 17β-hydroxysteroid dehydroge-
nase type 1.
Figure 2. Expression of enzymes associated with the local production of 
estrogens in human normal mammary tissue and breast carcinoma tissue. 
In the breast carcinoma tissue, STS, AROM and 17β‑ HSD1 tend to be over-
expressed, while EST is decreased. Melatonin decreases the expression of 
AROM, STS and 17β-HSD1, and increases the EST expression. Thus, mela-
tonin tends to modify the expression of the enzymes involved in the local 
synthesis of estrogens, causing it to be similar to the expression of enzymes in 
the mammary normal tissue. Figure modified from Cos et al (23). STS, sulfa-
tase; AROM, aromatase; 17β‑ HSD1, 17β-hydroxysteroid dehydrogenase type 
1; EST, estrogen sulfotransferase; E1S, estrone sulfate; E2S, estradiol sulfate.
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of promoters I.3 and II, and result in decreased aromatase 
expression (29,30). 
In addition, the antiaromatase and antisulfatase effects 
of melatonin have also been shown in cancer cell types other 
than breast cancer cells. In glioblastoma cells, which express 
estrogen receptors and have the ability to synthesize estrogens, 
melatonin also reduces the local production of estrogens by 
decreasing the activity of aromatase, sulfatase and 17β-HSD1, 
and downregulating aromatase, sulfatase and 17β-HSD1 
mRNA steady state levels (31,32).
This melatonin modulatory effect on the aromatase and 
sulfatase enzymes, at the tumor cell level, has also been 
described in vivo, in rats bearing 7,12-dimethylbenzan-
thracene-induced mammary tumors. The growth of these 
mammary tumors is estrogen-dependent and ovariectomy 
significantly reduces both the size and number of tumors, 
while the administration of testosterone or estrone sulfate to 
ovariectomized animals is able to maintain the tumor growth 
at the same level as the control (uncastrated) animals. The 
stimulatory effects of tumor development induced by testos-
terone (which depends on the local synthesis of estrogens from 
androgens), due to the aromatase action, or estrone sulfate 
(which depends on the estrogens locally formed by the action 
of the sulfatase enzyme on the biologically inactive estrogens), 
are suppressed by the administration of melatonin. Tumors 
from animals treated with melatonin have the lowest micro-
somal aromatase and sulfatase activity (14,33). 
3. Local synthesis of estrogens in peritumoral fibroblasts 
and melatonin
In breast tumors, the majority of aromatase and sulfatase activity 
and expression, the two principal pathways of synthesis of 
estrogens, are found in the fibroblast component of the adipose 
tissue and in vascular endothelial cells. The local biosynthesis 
of estrogens in breast cancer depends on paracrine interactions 
between malignant epithelial cells and proximal fibroblasts and 
vascular endothelial cells. Malignant epithelial cells secrete 
cytokines, including tumor necrosis factor α (TNF-α), inter-
leukin 6 (IL-6) and IL-11, which are upregulated by estrogens. 
These cytokines inhibit the differentiation of surrounding 
fibroblasts into mature adipocytes, through the selective 
inhibition of expression of peroxisome proliferator-activated 
receptor γ (PPARγ) and CCAAT/enhancer binding protein α 
(C/EBPα), and also stimulate aromatase expression in these 
undifferentiated fibroblasts (Fig. 3) (19,34,35). This biological 
phenomenon is commonly known as the desmoplastic reac-
tion or the accumulation of undifferentiated fibroblasts with 
high aromatase activity surrounding malignant epithelial cells. 
Tumor cells also secrete other factors, such as PGE2, which 
stimulate aromatase activity and expression in these undif-
ferentiated fibroblasts, as well as upregulating antiadipogenic 
cytokines.
3T3‑L1 is a fibroblast cell line that is initially fibroblastic 
but which, under appropriate conditions, differentiates into 
adipocytes (36). Melatonin treatment during the preadipocyte 
differentiation enhances the adipogenesis, and higher doses 
of melatonin induce more extensive deposits of lipid droplets 
and also induce a ~50% reduction in the aromatase activity 
of the cells, two indicators of adipogenic differentiation. It 
has been demonstrated that melatonin significantly increases 
the expression of PPARγ and C/EBPα, the two main regula-
tors of terminal adipogenesis (37). An approach to simulate 
in vitro the situation occurring in the mammary tumor is to 
use cocultures of malignant epithelial cells with fibroblasts or 
endothelial cells. The presence of malignant epithelial cells 
in the cocultures inhibits the differentiation of preadipocytes 
to adipocytes and reduces the intracytoplasmic triglyceride 
accumulation, an indicator of adipogenic differentiation. The 
presence of malignant cells also stimulates the aromatase 
activity in the fibroblasts. Melatonin counteracts the inhibi-
tory effect on adipocyte differentiation induced by malignant 
epithelial cells, and also counteracts the stimulatory effect of 
the presence of breast cancer cells on aromatase activity in 
fibroblasts (37‑39). 
The levels of antiadipogenic cytokines, TNF-α, IL-6 and 
IL-11, in the coculture media are 10-fold higher than those 
found in the culture of fibroblasts alone, since epithelial 
malignant cells, in the presence of fibroblasts, secrete these 
cytokines with the aim to inhibit the differentiation of preadi-
pocytes into adipocytes and to accumulate undifferentiated 
fibroblasts with high aromatase activity around malignant 
epithelial cells. The addition of melatonin to the cocultures 
decreases the concentrations of cytokines in the media and 
counteracts the stimulatory effect induced by the presence of 
malignant cells on the cytokines levels. Melatonin also induces 
a reduction in the TNF-α, IL-6 and IL-11 mRNA expression 
in breast cancer epithelial cells and fibroblasts (Fig. 3). The 
Figure 3. Epithelial-stromal interactions in breast tumors inhibit adipogenic 
differentiation and enhance estrogen formation by increasing the aromatase 
activity of the undifferentiated fibroblasts. All these actions are mediated 
by cytokines, such as TNF-α, IL-6 and IL-11, produced by malignant epi-
thelial cells. Melatonin reduces the formation of undifferentiated fibroblasts 
surrounding malignant epithelial cells by stimulating the differentiation 
of fibroblasts to mature adipocytes and adipogenesis, and by decreasing 
the aromatase activity of the fibroblasts and adipocytes through a down-
regulatory action on the expression of antiadipogenic cytokines, which 
decreases the levels of these cytokines. Lower levels of TNF-α, IL-6 and 
IL‑11 stimulate the differentiation of fibroblasts and decrease the aromatase 
activity and expression. Melatonin also decreases the production of PGE2 by 
malignant cells, which upregulates aromatase expression both in the tumor 
itself and in the surrounding adipose tissue, and enhances the production of 
IL‑11 by tumor cells. Figure modified from Álvarez‑García et al (39) and 
Cos et al (23). TNF-α, tumor necrosis factor-α; IL, interleukin.
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addition of luzindole, a melatonin receptor antagonist, prevents 
this inhibitory effect of melatonin on cytokines expression, 
indicating that melatonin acts through known melatonin 
receptor-mediated mechanisms (39).
In summary, melatonin may reduce the level of undif-
ferentiated fibroblasts surrounding malignant epithelial cells 
by stimulating the differentiation of fibroblasts to mature 
adipocytes and adipogenesis, and by decreasing the aromatase 
activity of the fibroblasts through a downregulatory action on 
the expression of antiadipogenic cytokines, which decreases 
the levels of these cytokines. Lower levels of TNF-α, IL-6 
and IL‑11 allow the differentiation of fibroblasts, as well as 
decreasing the aromatase activity and expression. Melatonin 
also decreases the production of PGE2 by malignant cells, 
which downregulates aromatase expression and cytokine 
production in the tumor itself and in the surrounding adipose 
tissue. Lower levels of aromatase lead to lower levels of estro-
gens, resulting in decreased growth and development of the 
breast tumor (Fig. 3).
4. Local synthesis of estrogens in peritumoral endothelial 
cells and melatonin
Endothelial cells also represent a critical cellular element in 
the tumor microenvironment, which play a crucial role in the 
growth and progression of breast tumors. They are another 
source of estrogens, as they also express aromatase (40,41). 
Promoter I.7 is a novel breast cancer-associated aromatase 
promoter mainly active in vascular endothelial cells, and is 
upregulated in breast cancer tissue (42). Excessive aroma-
tase expression via promoters I.3, II and I.7, and consequent 
increase in estrogen biosynthesis in malignant epithelial cells, 
undifferentiated adipose fibroblasts and adjacent endothelial 
cells contribute to the development and progression of breast 
cancer. In addition, endothelial cells provide structural and 
biochemical support for tumor growth and progression of 
cancer through control of angiogenesis. Vascular endothelial 
growth factor (VEGF) secreted by breast cancer cells is essen-
tial for the expansion of breast cancer and may function in both 
paracrine and autocrine manners to promote the proliferation, 
growth, survival and migration of endothelial cells (43,44).
In endothelial cells, melatonin decreases the aromatase 
activity and expression mainly by inducing a significant 
downregulation in aromatase expression specifically driven by 
promoter I.7, the major promoter directing aromatase expres-
sion in endothelial cells (Fig. 4) (45).
VEGF, a major regulator of endothelial growth, added to 
endothelial cell cultures stimulates the proliferation of these 
cells and melatonin counteracts this effect (46). Melatonin 
reduces VEGF mRNA expression in human breast cancer 
(MCF-7) cells and also reduces VEGF levels in cell culture 
media of malignant epithelial cells (Fig. 4). Cocultures of 
breast malignant epithelial cells and endothelial cells is an 
approach to simulate in vitro the paracrine interaction between 
these cells in the mammary tumors. The presence of malig-
nant epithelial cells in the cocultures is able to stimulate the 
endothelial cell proliferation and increase the VEGF levels 
in the culture media. Melatonin counteracts the stimulatory 
effects on endothelial cell proliferation and on VEGF protein 
levels in the co culture media. The changes in endothelial cell 
proliferation induced by melatonin are mediated by an inhibi-
tion of the synthesis of VEGF in malignant epithelial cells. 
Conditioned media from malignant cells stimulate endothelial 
cell proliferation, and this effect is significantly counteracted 
by anti-VEGF and melatonin (46). 
All these findings suggest that melatonin may play a role 
in the paracrine interactions between malignant epithelial 
cells and proximal endothelial cells, through a downregula-
tory action on VEGF expression in human breast cancer cells, 
which decreases the levels of VEGF surrounding endothelial 
cells. Lower levels of VEGF may be important in reducing the 
number of estrogen-producing cells proximal to malignant cells, 
as well as in decreasing tumoral angiogenesis. Antiangiogenic 
activity of melatonin against the pro-angiogenic effects of 
breast cancer cells has also been described (47). Recently, it 
has been demonstrated that melatonin has effects on different 
steps of the angiogenic process in endothelial cell cultures (47). 
Melatonin strongly inhibits the proliferation of endothelial 
cells and counteracts the stimulatory effect induced by estra-
diol. In Transwell assays, melatonin has been identified to 
reduce the number of endothelial cells that invaded through 
a basement membrane in response to VEGF. Endothelial cell 
migration is essential for the formation of new blood vessels 
during neo-angiogenesis. Melatonin treatment strongly 
inhibits the migration of endothelial cells in wound-healing 
assays. Another important step during neo-angiogenesis is 
the formation of tubes by endothelial cells. It is established 
that VEGF increases the formation of a branching network of 
tubes. Melatonin disrupts the tube formation and counteracts 
the VEGF-stimulated tubular network formation by endothe-
lial cells. In addition, conditioned media collected from breast 
cancer cells are angiogenically active and stimulate tubule 
length formation. This effect is significantly counteracted by 
Figure 4. Role of melatonin in the paracrine interactions that occur between 
malignant epithelial cells and proximal endothelial cells. Melatonin may be 
important in reducing endothelial cell proliferation, invasion, migration and 
tube formation, through a downregulatory action on VEGF and PGE2. PGE2 
induced by VEGF may directly promote angiogenesis and melatonin through 
its downregulatory action on the expression of cyclooxygenase enzymes, 
decreasing the levels of PGE2 and reducing the levels of angiogenesis. 
Melatonin also inhibits aromatase activity and expression in endothelial cells 
by regulating the gene expression of specific aromatase promoter region I.7, 
thereby reducing the local production of estrogens. VEGF, vascular endothe-
lial growth factor; PGE2, prostaglandin E2.
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the addition of either anti-VEGF antibody or melatonin, which 
suggests that the melatonin-induced decrease of capillary 
structure formation stimulated by conditioned media from 
MCF-7 cells may occur as a result of inhibition of VEGF 
activity (47). 
Melatonin may play a role in the paracrine interactions that 
take place between malignant epithelial cells and proximal 
endothelial cells, acting by different mechanisms. On one hand, 
melatonin exerts antiangiogenic effects and may be important 
in reducing endothelial cell proliferation, invasion, migra-
tion and tube formation, through a downregulatory action on 
VEGF and PGE2 (Fig. 4). PGE2 synthesis induced by VEGF 
may directly promote angiogenesis and melatonin through its 
downregulatory action on the expression of COX enzymes, 
which decrease the levels of PGE2 and reduce angiogenesis. 
On the other hand, melatonin inhibits aromatase activity and 
expression in endothelial cells by regulating gene expression 
of specific aromatase promoter regions, thereby reducing the 
local production of estrogens (Fig. 4).
5. Conclusions
Several lines of evidence highlight the contribution of the tumor 
microenvironment to its growth and maintenance. Cells imme-
diately adjacent to the tumor are not only passive structural 
support but also active elements in tumor progression. Among 
the numerous different cell types surrounding breast cancer 
cells, the most abundant are those that compose mammary 
adipose tissue. Ninety percent of these resident cells of adipose 
tissue are fibroblasts, the precursors of mature adipocytes, and 
7% are endothelial cells (35). Epithelial-stromal interactions in 
breast tumors inhibit adipogenic differentiation and enhance 
estrogen formation by increasing the aromatase activity of the 
undifferentiated fibroblasts. All these actions are mediated 
by cytokines, such as TNF-α, IL-11 and IL-6, produced by 
malignant epithelial cells. Melatonin may reduce the forma-
tion of undifferentiated fibroblasts surrounding malignant 
epithelial cells by stimulating the differentiation of fibroblasts 
to mature adipocytes and adipogenesis, and by decreasing the 
aromatase activity of the fibroblasts and adipocytes through 
a downregulatory action on the expression of antiadipogenic 
cytokines, which decrease the levels of these cytokines. Lower 
levels of TNF-α, IL-6 and IL-11 stimulate the differentiation 
of fibroblasts and decrease the aromatase activity and expres-
sion. Melatonin also decreases the production of PGE2 by 
malignant cells, which upregulates aromatase expression both 
in the tumor itself and in the surrounding adipose tissue and 
enhances the production of IL-11 by tumor cells. Endothelial 
cells also produce estrogens from androgens precursors. 
Melatonin decreases the activation of promoter I.7 and results 
in decreased aromatase expression. In addition, melatonin 
reduces endothelial cell proliferation, invasion, migration and 
tube formation, through a downregulatory action on VEGF. 
This melatonin modulation of epithelial-stromal interactions 
favors lower numbers of undifferentiated fibroblasts, angio-
genesis and reduced local estrogen concentrations in breast 
tumors.
Melatonin may play a role in the paracrine interactions 
that occur between malignant epithelial cells and proximal 
adipose and endothelial cells, through a downregulatory 
action on cytokines and growth factors produced by breast 
tumor cells. The actions of melatonin described in the present 
review involve antiproliferative, antiaromatase and antiangio-
genic effects, and suggest that melatonin may potentially be 
beneficial as an anticancer drug in the prevention and treat-
ment of estrogen-dependent mammary tumors. Therefore, this 
creates interesting possibilities for the clinical applications of 
melatonin in breast cancer.
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